Prostate Cancer Clinical Trial
— DARIUSOfficial title:
A Randomized Non-comparative Phase II Multicentric Trial on Short Term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.
Status | Recruiting |
Enrollment | 62 |
Est. completion date | February 2030 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18, 2. Histological diagnosis of prostate malignancy cancer 3. Cancer without loco-regional or distant metastasis (tumor assessment must comprise at least Pelvic MRI AND thoraco-abdomino-pelvic contrast-enhanced CT-Scan AND Bone Scintigraphy. (Note that additional assessment by PET-Scan is allowed as per investigator judgement), 4. Unfavorable intermediate risk prostate cancer diagnosis defined by the NCCN Guidelines. One of the following criteria is sufficient to define an unfavorable intermediate risk prostate cancer: - Gleason = 7 (4+3) - = 50% of thecore of biopsies need to be positive for adenocarcinoma If these criteria are not being identified, two or three of the following criteria are necessary to define unfavorable intermediate risk prostate cancer: - PSA value between 10-20 ng/ml - Gleason 7 (3+4) or 6 - T2b (clinical or radiological) Note: patients with iT3a can be included only if gleason score is 6 and PSA less than 20 . 5. Patients newly diagnosed with an unfavorable intermediate risk prostate cancer according to the protocol criteria or previously diagnosed with low risk (Gleason score < 6, clinical stage < T2a, and PSA< 10) prostate cancer progressing to eligible risk disease according to the protocol criteria within 30 days before registration 6. Patients must have a life expectancy of at least 5 years, 7. Performance status ECOG = 2, 8. Patients without contra-indications to EBRT as per physician judgement, 9. Patients with adequate organ function defined by all the following laboratory values 10. Available archived paraffin-embedded tumor sample for research purpose, 11. Patients with a social security in compliance with the french law, 12. Voluntary signed and dated written informed consent prior to any study specific procedure, 13. Men must agree to use an effective method of contraception throughout the treatment period and for one week after discontinuation of treatment. Exclusion Criteria: 1. Stage T3b-T4 prostate cancer by clinical examination or radiologic evaluation, 2. Patients with Gleason score =8, 3. Patients with PSA >20 ng/ml, 4. Presence of loco-regional or distant metastasis, 5. Contra-indications to MRI and to contrast-enhanced CT-scan, 6. Hypogonadism or severe androgen deficiency as defined by screening serum testosterone less than 50 ng/dL or below the normal range for the institution. 7. Previous prostate cancer treated by androgen deprivation, chemotherapy, surgery, or radiotherapy, 8. Patients with previous orchiectomy 9. Patients actively receiving or having received within 6 months prior enrollment any concurrent androgens, anti-androgens, estrogens, or progestational agents, 10. Patients having received ketoconazole, finasteride or dutasteride within 30 days of inclusion, 11. Previous and current malignancies other than prostate cancer within the last 5 years with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, acute lymphoblastic leukemia, non-muscle invasive bladder cancer, 12. Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection), 13. History of cerebrovascular accident (within the last 6 months) 14. Impaired cardiac function as defined in the Protocol 15. Uncontrolled hypertension 16. Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of study drug, 17. Major surgery within 4 weeks prior enrolment except pelvic lymph-nodes dissection, 18. Known hypersensitivity to any involved study drug or of its formulation components, to natural gonadotrophin releasing hormone or its analogues 19. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption syndrome 20. Men who are not using an effective method of contraception as previously described 21. Use of herbal or alternative remedies that may affect hormonal status such as Prostasol or PC-SPES, 22. History of non-compliance to medical regimens or inability to grant consent, 23. Patient unable to follow and comply with the study procedures because of any geographical, social or psychpsychological reasons, 24. Individuals under judicial protection or deprived of liberty. 25. Inability to swallow or to give subcutaneous or intramuscular injections. |
Country | Name | City | State |
---|---|---|---|
France | Sainte Catherine, Institut du Cancer Avignon-Provence | Avignon | |
France | CHRU Besançon | Besançon | |
France | Institut Bergonie | Bordeaux | |
France | CHRU Brest - Hôpital Morvan | Brest | |
France | Assitance Publique des Hôpitaux de Marseille - CHU La Timone | Marseille | |
France | Hôpital de la Pitié Salpétrière | Paris | |
France | CHP Saint-Grégoire | Saint-Grégoire | |
France | Institut de Cancérologie de l'Ouest - Site René Gauducheau | Saint-Herblain | |
France | Clinique Pasteur | Toulouse | |
France | IUCT Oncopôle | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Institut Bergonié | Bayer |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of efficacy in terms of 6-month biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 6 months after randomization | |
Secondary | Assessment of efficacy in terms of biological response at the end of darolutamide or ADT | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | An expected average of 6 months | |
Secondary | 2-month biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 2 months after randomization | |
Secondary | 3-month biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 3 months after the end of radiotherapy | |
Secondary | 6-month biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 6 months after the end of radiotherapy | |
Secondary | 9-month biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 9 months after the end of radiotherapy | |
Secondary | 2-year biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 2 years after randomization | |
Secondary | 3-year biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 3 years after randomization | |
Secondary | 5-year biological response | Biological response is defined as a PSA concentration <=0.1ng/mL according to Phoenix's criteria | 5 years after randomization | |
Secondary | 2-year biochemical progression-free survival (bPFS) | Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first. | 2 years | |
Secondary | 3-year biochemical progression-free survival (bPFS) | Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first. | 3 years | |
Secondary | 5-year biochemical progression-free survival (bPFS) | Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first. | 5 years | |
Secondary | 2-year metastasis free survival (MFS) | Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy) | 2 years | |
Secondary | 3-year metastasis free survival (MFS) | Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy) | 3 years | |
Secondary | 5-year metastasis free survival (MFS) | Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy) | 5 years | |
Secondary | 2-year disease free survival (DFS) | Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause) | 2 years | |
Secondary | 3-year disease free survival (DFS) | Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause) | 3 years | |
Secondary | 5-year disease free survival (DFS) | Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause) | 5 years | |
Secondary | 2-year prostate cancer-specific survival (PCSS) | Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death | 2 years | |
Secondary | 3-year prostate cancer-specific survival (PCSS) | Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death | 3 years | |
Secondary | 5-year prostate cancer-specific survival (PCSS) | Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death | 5 years | |
Secondary | 2-year overall survival (OS) | Overall survival is defined as the delay between the date of randomization and the date of death (all cause). | 2 years | |
Secondary | 3-year overall survival (OS) | Overall survival is defined as the delay between the date of randomization and the date of death (all cause). | 3 years | |
Secondary | 5-year overall survival (OS) | Overall survival is defined as the delay between the date of randomization and the date of death (all cause). | 5 years | |
Secondary | Time to testosterone recovery | Time to testosterone recovery defined as the time from randomization to the time when serum of total testosterone level increases to above the lower limit of the normal range. | An expected average of 6 months | |
Secondary | Acute safety profile independently for each treatment strategy | Toxicity graded using the Common Terminology Criteria for Adverse Events version 5 | 3 months | |
Secondary | Late 2-year safety profile independently for each treatment strategy | Toxicity graded using the Common Terminology Criteria for Adverse Events version 5 | 2 years | |
Secondary | Late 3-year safety profile independently for each treatment strategy | Toxicity graded using the Common Terminology Criteria for Adverse Events version 5 | 3 years | |
Secondary | Late 5-year safety profile independently for each treatment strategy | Toxicity graded using the Common Terminology Criteria for Adverse Events version 5 | 5 years | |
Secondary | Assessment of quality of life | Quality of life will be assessed as per the EORTC QLQ-C30 questionnaire and prostate cancer module PR-25 | Throughout the follow-up period, an expected average of 5 years | |
Secondary | Assessment of erectile dysfunction | Erectile dysfunction will be assessed as per IIEF5 | Throughout the follow-up period, an expected average of 5 years | |
Secondary | Assessment of symptoms of benign prostatic hyperplasia | Symptoms of benign prostatic hyperplasia will be assessed as per IPSS | Throughout the follow-up period, an expected average of 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |